

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



開拓藥業有限公司\*

**KINTOR PHARMACEUTICAL LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9939)**

## **CHANGE OF DIRECTORS**

The Board announces that, with effect from 31 January 2022:

- (a) Ms. Yan LU was appointed as an executive Director; and
- (b) Mr. Gang LU resigned as a non-executive Director.

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (“**Directors**”, each a “**Director**”) of Kintor Pharmaceutical Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) hereby announces that Ms. Yan LU (盧燕) (“**Ms. LU**”) was appointed as an executive Director with effect from 31 January 2022, pursuant to rule 13.51(2) of the Listing Rules.

Ms. LU, aged 39, was appointed as the Chief Financial Officer of the Group in December 2019 and a joint company secretary of the Company in November 2021. Ms. LU is primarily responsible for financial internal control, investor relations, public relations and treasury management of the Group. Prior to joining the Group, Ms. LU has over 13 years of experience in investment banking business. Ms. LU joined GF Capital (Hong Kong) Limited in July 2018 with her last position as the director, head of investment banking business and managing director. From September 2007 to July 2018, Ms. LU worked at UBS Securities Hong Kong Limited with her last position as an executive director in the Asian healthcare group. She has been a signing Principal for Hong Kong initial public offerings (IPO) since 2014. Ms. LU obtained her master’s degree in finance from Guanghua School of Management in Peking University (北京大學), and her bachelor’s degree in finance in Renmin University of China (中國人民大學).

Ms. LU has entered into a service contract with the Company for an initial term of three years commencing on 31 January 2022, subject to retirement by rotation and re-election at the general meetings of the Company pursuant to the articles of association of the Company. The remuneration packages of Directors are determined by reference to the Company's performance and profitability, the prevailing market conditions and the performance or contribution of each Director. Under her contract of employment, Ms. LU is entitled to an annual salary which together with other benefits amounting to approximately HK\$5.25 million and is eligible to receive a performance-related discretionary bonus. Pursuant to her service contract, Ms. LU will not receive any emoluments from the Company for her appointment as an executive Director.

As at the date of this announcement, Ms. LU is interested in 2.8 million restricted share units (representing 2.8 million underlying shares of the Company) under the employee incentive scheme of the Company.

Save as disclosed above, to the best knowledge and belief of the Board and having made all reasonable enquiries, as at the date of this announcement, Ms. LU (i) did not hold other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the three years preceding the date of this announcement; (ii) did not have any relationship with any directors, senior management or substantial or controlling shareholder (as defined under the Listing Rules) of the Company; (iii) did not hold any other positions in the Company or any of its subsidiaries; and (iv) did not have, and was not deemed to have any interest in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any other matters in relation to Ms. LU's appointment as an executive Director that need to be brought to the attention of the Shareholders, nor is there any other information that should be disclosed by the Company pursuant to rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express its warm welcome to Ms. LU to the Board.

## **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The Board hereby announces that Mr. Gang LU ("Mr. LU") resigned as a non-executive Director with effect from 31 January 2022 due to pursuit of his personal commitments, pursuant to rule 13.51(2) of the Listing Rules.

Mr. LU has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to take this opportunity to extend its sincere gratitude to Mr. LU for his valuable contribution to the Company during his tenure of office.

By order of the Board  
**KINTOR PHARMACEUTICAL LIMITED**  
**Dr. Youzhi Tong**

*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, 3 February 2022

*As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Ms. Yan Lu; the non-executive Directors are Mr. Weipeng Gao, Dr. Yan Wang, and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.*

\* *For identification purposes only*